NAECB NAECB Immunotherapy & Allergen Management

Question 1

Allergen immunotherapy (AIT) works primarily by:

Accepted Answer

Inducing immune tolerance through repeated allergen exposure

Answer

AIT induces immunological tolerance by shifting the immune response from Th2-dominant allergic inflammation toward a regulatory, tolerant phenotype.

Question 2

The build-up phase of subcutaneous allergen immunotherapy (SCIT) typically involves:

Accepted Answer

Weekly injections with increasing allergen doses

Answer

During the build-up phase, weekly injections with progressively increasing allergen concentrations are given until the target maintenance dose is reached.

Question 3

What is the recommended observation period after each subcutaneous immunotherapy injection in a US clinic?

Accepted Answer

20–30 minutes

Answer

Patients must be observed for 20–30 minutes after SCIT injections because most systemic reactions occur within this window.

Question 4

Sublingual immunotherapy (SLIT) tablets approved in the US are indicated for which conditions?

Accepted Answer

Grass pollen, dust mite, and ragweed allergies

Answer

FDA-approved SLIT tablets in the US target grass pollen, house dust mite, and short ragweed allergens for allergic rhinitis and asthma.

Question 5

Which of the following is an absolute contraindication to initiating allergen immunotherapy?

Accepted Answer

Severe or uncontrolled asthma (FEV1 < 70% predicted)

Answer

Severe or uncontrolled asthma with FEV1 below 70% predicted is an absolute contraindication because systemic reactions carry higher risk of fatal bronchospasm.

NAECB Exam Practice Test

NAECB Exam Practice Test

NAECB NAECB Immunotherapy & Allergen Management